Cancer Antigen (CA-125)

• If you are currently undergoing treatment for ovarian cancer, your doctor may recommend this test to track your response to therapy.
• After completing ovarian cancer treatment, regular CA-125 testing may be part of your follow-up plan to monitor for any signs of recurrence.
• If your doctor has found a suspicious pelvic mass or fluid in your abdomen, this test may be ordered to help evaluate the nature of the finding.
• If you are experiencing persistent or new symptoms such as bloating, pelvic or abdominal pain, difficulty eating, or changes in urinary habits, which could, in rare cases, be associated with ovarian issues. (Note: These symptoms are common and usually not due to ovarian cancer.)

• Women who have been diagnosed with ovarian cancer and are undergoing treatment, to monitor the effectiveness of therapy.
• Women who have completed treatment for ovarian cancer, for surveillance and early detection of recurrence.
• Individuals with a suspicious pelvic mass or fluid accumulation (ascites), where this test may help in initial evaluation alongside other diagnostic tools.
• Women with a strong family history of ovarian cancer, as part of a comprehensive risk assessment strategy discussed with their healthcare provider.

The Cancer Antigen 125 (CA-125) test is primarily utilized as a tumor marker. While not a definitive diagnostic tool on its own, it is commonly used in conjunction with other clinical and imaging findings for:

• Monitoring the effectiveness of treatment for women diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. A decrease in CA-125 levels often indicates a positive response to therapy.
• Detecting recurrence of ovarian cancer after successful treatment. Rising CA-125 levels can signal a return of the disease, often before symptoms appear or can be detected by imaging.
• Evaluating the nature of a suspicious pelvic mass, especially in postmenopausal women. While an elevated CA-125 does not confirm cancer, it can, when combined with other risk factors and imaging, help a physician determine if further investigation, such as biopsy or surgery, is warranted.
• Assessing prognosis in certain gynecological cancers.

It is important to remember that CA-125 can be elevated in various benign conditions (e.g., endometriosis, fibroids, pregnancy, liver disease, pancreatitis) and even during menstruation, so it is not specific enough for cancer screening in asymptomatic women.

It is crucial to understand that an elevated CA-125 level does not definitively diagnose cancer. Many non-cancerous conditions, such as endometriosis, uterine fibroids, pelvic inflammatory disease, or even menstruation and pregnancy, can lead to elevated CA-125 levels. Conversely, a normal CA-125 level does not exclude the presence of ovarian cancer, especially in its early stages.

Test results can vary depending on the specific assay method used, making direct comparisons between results from different laboratories or different test procedures challenging. Patients who have received treatments involving monoclonal mouse antibodies may experience erroneous findings. As with all diagnostic tests, the CA-125 result should always be interpreted by a healthcare provider in conjunction with your complete medical history, clinical examination findings, and other relevant diagnostic tests.